Histocompatibility and Cryopreservation Laboratory, Rio de Janeiro State University, Rio de Janeiro, Brazil.
J Med Virol. 2015 Oct;87(10):1702-15. doi: 10.1002/jmv.24227. Epub 2015 May 12.
The single nucleotides polymorphisms analyses in the regions near the IL28B gene in patients chronically infected with genotype 1 hepatitis C virus (HCV) are an important predictive factor for sustained virological response (SVR). The aim was to assess the predictive value of the polymorphisms of the IL28B/IFNL3 gene in patients chronically infected with genotype 1 for the viral clearance obtained after initial treatment including admixed populations. A systematic review was conducted, using a meta-analysis in the PubMed, Embase, LILACS, and SCIELO using MesH and DECS in 42 studies. The parameters were IL28B polymorphisms, rs12979860, rs8099917, and rs12980275, SVR ratio, and OR (odds ratio). OR and confidence Interval of 95% (95%CI), were calculated by fixed or random effects models. Heterogeneity, sensitivity analysis, and publication bias were also performed. Significant differences were noted between carriers groups with the major versus minor allele at rs12979860 CC versus CT/TT-genotype (OR = 4.18; 95%CI = 3.37-5.17), rs8099917 TT versus TG/GG-genotype (OR = 4.07; 95%CI = 2.94-5.63), and rs12980275 AA versus AA/AG-genotype (OR = 5.34; 95%CI = 1.60-17.82). There was selection bias in the rs8099917 analysis (Egger's regression P = 0.049), which reversed after performing a sensitivity analysis (P = 0.510). The incorporation of SNP analyses in IL28B/IFNL3 gene during the diagnosis process in Brazil should be used as a complementary tool to determine the appropriate treatment for HCV genotype 1. Here, we confirm that the rs12979860 CC, rs8099917 TT, and rs12980275 AA genotype-carriers have favorable responses to standard therapy, including two studies with Brazilian population, and this information should be considered.
在慢性感染基因型 1 丙型肝炎病毒 (HCV) 的患者中,IL28B 基因附近的单核苷酸多态性分析是持续病毒学应答 (SVR) 的重要预测因素。目的是评估 IL28B/IFNL3 基因多态性在慢性感染基因型 1 的患者中的预测价值,以获得包括混合人群在内的初始治疗后的病毒清除。使用 PubMed、Embase、LILACS 和 SCIELO 中的 MesH 和 DECS 进行系统评价,并进行荟萃分析,共纳入 42 项研究。参数为 IL28B 多态性 rs12979860、rs8099917 和 rs12980275、SVR 比值和 OR(比值比)。通过固定或随机效应模型计算 OR 和 95%置信区间 (95%CI)。还进行了异质性、敏感性分析和发表偏倚。在 rs12979860 CC 与 CT/TT 基因型携带者与次要等位基因相比,CC 与 CT/TT 基因型携带者的差异有统计学意义(OR=4.18;95%CI=3.37-5.17),rs8099917 TT 与 TG/GG 基因型携带者与次要等位基因相比,TT 与 TG/GG 基因型携带者的差异有统计学意义(OR=4.07;95%CI=2.94-5.63),rs12980275 AA 与 AA/AG 基因型携带者与次要等位基因相比,AA 与 AA/AG 基因型携带者的差异有统计学意义(OR=5.34;95%CI=1.60-17.82)。rs8099917 分析存在选择偏倚(Egger 回归 P=0.049),但在进行敏感性分析后(P=0.510),偏倚得到逆转。在巴西,在诊断过程中纳入 IL28B/IFNL3 基因的 SNP 分析应该作为确定 HCV 基因型 1 适当治疗方法的补充工具。在这里,我们确认 rs12979860 CC、rs8099917 TT 和 rs12980275 AA 基因型携带者对标准治疗有良好的反应,包括两项巴西人群的研究,应考虑这些信息。